海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
- Prostate Cancer;Castration Resistant Prostate Cancer;Pain;Prostatic Neoplasms
- Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, United States
- 2012-05-22
Recruiting
- A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
- Metastatic Castrate Resistant Prostate Cancer;C61 - Malignant neoplasm of prostate
- Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, France, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Turkey, United Kingdom, United States
- 2014-11-13
Recruiting
- A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
- Metastatic Castration Resistant Prostate Cancer;C61 - Malignant neoplasm of prostate
- Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Switzerland, Turkey, United Kingdom
- 2015-06-25
Not Recruiting
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Hungary, Ireland, Netherlands, Spain, United Kingdom, United States
- 2013-11-05
Not Recruiting
- A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- Leuprolide Acetate) in Combination With TAXOTERE® (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Brazil, Canada, France, Germany, India, Israel, Italy, Mexico, Netherlands, Poland, Russian Federation, South Africa, Turkey, United Kingdom, United States
- 2015-11-11
Not Recruiting
- Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.
- progressive castration-resistant prostate cancer. br>MedDRA version: 16.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Germany, Greece, Ireland, Italy, Japan, Netherlands, New Zealand, Portugal, United Kingdom, United States
- 2012-06-12
Recruiting
- Multicentric, prospective, randomized study to evaluate the effect of standard drug therapy with or without radical prostatectomy (RP) in patients with limited bone metastatic prostate cancer
- ;C61 - Malignant neoplasm of prostate
- Austria, Germany, Sweden
- 2015-10-02
Recruiting
- A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
- Prostatic Neoplasms, Castration-Resistant;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Switzerland, Taiwan, Province of China, United Kingdom, United States
- 2017-07-17
Not Recruiting
- A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
- Prostate Cancer # Castration Resistant Prostate Cancer # Pain # Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, United States
- 2013-08-06
Not Recruiting
- A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, United Kingdom, United States
- 2015-11-12